Epratuzumab - CISMeF

Preferred Label : Epratuzumab;

NCIt synonyms : hLL2; IMMU-HLL2;

NCIt definition : A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).;

UNII : 3062P60MH9;

CAS number : 205923-57-5;

Drug name : LymphoCide;

Molecule name : AMG 412;

NSC code : 716711;

Codes from synonyms : CDR0000045431; 194;

Details

Origin ID

C1887;

UMLS CUI

C1120776;

Automatic exact mappings (from CISMeF team)
- HLL2 [MeSH concept]
Currated CISMeF NLP mapping
- epratuzumab [MeSH Supplementary Concept]
- epratuzumab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- epratuzumab [MeSH Supplementary Concept]
- epratuzumab [MeSH concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Cell Receptor CD22 [NCIt concept]
is_component_of_chemotherapy_regimen
- Cyclophosphamide/Doxorubicin/Epratuzumab/Prednisone/Rituximab/Vincristine [NCIt concept]
- Epratuzumab/Rituximab [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients